Investing
Regeneron beats quarterly profit estimates
© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid/File Photo
(Reuters) – Regeneron Pharmaceuticals Inc (NASDAQ:) beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent.
Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts’ estimates of $9.56, according to Refinitiv data.
(This story has been corrected to remove reference to Eylea in the headline and paragraph 1)
Read the full article here
-
Investing5 days ago
This All-Access Pass to Learning Is Now $20 for Black Friday
-
Passive Income5 days ago
How to Create a Routine That Balances Rest and Business Success
-
Side Hustles6 days ago
Apple Prepares a New AI-Powered Siri to Compete With ChatGPT
-
Side Hustles3 days ago
A Macy’s Employee Made Accounting Errors Worth $132 Million
-
Investing2 days ago
Factbox-How Trump can overhaul US financial regulators when he takes office By Reuters
-
Passive Income6 days ago
Customers Want More Than Just a Product — Here’s How to Keep Up
-
Side Hustles7 days ago
MIT Gives Free Tuition For Families Earning $200,000 or Less
-
Side Hustles5 days ago
Gift the Power of Language Learning with This Limited-Time Price on Babbel